Abstract |
The discovery of human epidermal growth factor receptor 2 (HER2) and its role in the biology of breast cancer, and the subsequent development of HER2-targeted therapies, have dramatically improved clinical outcomes for millions of women with early-stage and advanced HER2-positive breast cancer. This review discusses the treatment of primary, nonmetastatic HER2-positive breast cancer in the adjuvant and neoadjuvant settings--settings in which tremendous progress has been made. Novel approaches, including the use of combinations of HER2-targeted therapies, are examined. Future challenges include refining such treatments, reducing toxicity in those who have low-risk disease, and simultaneously developing innovative therapies for patients who remain at high risk for relapse with existing treatment options.
|
Authors | Ursa Brown-Glaberman, Zoneddy Dayao, Melanie Royce |
Journal | Oncology (Williston Park, N.Y.)
(Oncology (Williston Park))
Vol. 28
Issue 4
Pg. 281-9
(Apr 2014)
ISSN: 0890-9091 [Print] United States |
PMID | 24839797
(Publication Type: Journal Article, Review)
|
Chemical References |
- ERBB2 protein, human
- Receptor, ErbB-2
|
Topics |
- Breast Neoplasms
(drug therapy, enzymology)
- Chemotherapy, Adjuvant
- Female
- Humans
- Molecular Targeted Therapy
- Neoadjuvant Therapy
- Receptor, ErbB-2
(metabolism)
|